)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cosciens Biopharma
Cosciens Biopharma (CSCI) investor relations material
Cosciens Biopharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary11 Aug, 2026
Executive summary
Achieved Q2 2026 consolidated net loss of $0.2 million, a significant improvement from $2.7 million net loss in Q2 2025, driven by higher gross margins, increased sales, and reduced expenses.
First half of 2026 saw consolidated net income of $10.6 million, reversing a $6.4 million net loss in the same period last year, mainly due to $10.9 million income from discontinued operations and operational efficiencies.
Shareholders approved a share reorganization, enabling suspension of SEC reporting obligations and expected annualized cost savings.
Financial highlights
Q2 2026 revenue rose to $3.1 million from $2.4 million in Q2 2025; first half 2026 revenue was $5.0 million, up from $3.8 million year-over-year.
Q2 2026 total operating expenses dropped to $1.3 million from $2.6 million in Q2 2025, with significant reductions in SG&A and R&D costs.
Cash and cash equivalents stood at $5.3 million as of June 30, 2026.
Outlook and guidance
Focus remains on supporting subsidiary Ceapro’s growth and exploring opportunities for greater scale as a public company.
Anticipates significant cost savings from reduced U.S. regulatory compliance following SEC reporting suspension.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cosciens Biopharma
- Board re-elections, auditor appointment, and share consolidation/split were all approved.CSCI
AGM 2026 - Returned to profitability in Q1 2026, driven by discontinued operations and lower expenses.CSCIQ1 2026
- Restructuring and subsidiary exit drove lower losses and improved cost structure in 2025.CSCIQ4 2025
- Operating expenses fell 59% and net loss narrowed in Q3 2025 amid restructuring and Nasdaq delisting.CSCIQ3 2025
- Q2 2025 saw revenue growth, cost cuts, Nasdaq delisting, and major leadership changes.CSCIQ2 2025
- Q3 2024 net loss widened on higher R&D and merger costs; new product launches on track.CSCIQ3 2024
- Revenue rose but net loss widened due to higher R&D and SG&A costs; DETECT trial data expected Q3.CSCIQ2 2024
- Six directors elected, auditor reappointed, and company name change approved; no questions asked.CSCIAGM 2024
- Revenue up 35% but net loss deepened as COSCIENS pivots to natural-based products.CSCIQ4 2024
Next Cosciens Biopharma earnings date
Q3 202618 Nov, 2026
Cosciens Biopharma
Next Cosciens Biopharma earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cosciens Biopharma Inc is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. The company targets therapeutic areas including oncology, immunology, and central nervous system disorders. It employs proprietary drug discovery platforms and engages in clinical development activities. The company is headquartered in Suzhou, China, and its shares are listed on the SSE STAR Market.